Research and Markets (http://www.researchandmarkets.com/research/hhsmsd/europe_orphan) has announced the addition of the "Europe Orphan Drug Market & Clinical Trial Insight 2015" report to their offering.

It has been estimated that Europe has witnessed more than 100 therapies for rare diseases being approved since 2000, when the European Commission introduced incentives to encourage the development of these drugs. The share of R&D for orphan medicinal products development as a proportion of total biopharmaceutical industry's R&D has been increasing significantly over the years. This is strengthened by the fact that almost all companies which have been set up recently to develop orphan medicinal products have their extensive R&D plants and staff located in the European Union. This shows the significance of the region and its level of attractiveness.

Additionally, the investment in R&D by the European companies for developing orphan medicinal products has increased by more than 200%, while the total number of employees in these companies has recorded an increase of more than 150% since 2000. With the long durations of lead times in the biopharmaceuticals industry for R&D projects, it is most likely that the EU Regulation for Orphan medicinal products would have a significant impact in the coming years.

Europe Orphan Drug Market & Clinical Trial Insight 2015 Report Highlights & Findings:

  • Europe Orphan Drug Market Overview
  • In-depth Insight on Regulatory Framework & for Orphan Drugs
  • Application Procedure for Seeking Orphan Drug Status
  • Comprehensive Insight on Orphan Drug Clinical Pipeline
  • Europe Orphan Drug Clinical Pipeline: 326 Drugs
  • Majority Orphan Designated Drugs in Phase-II : 111
  • Marketed Orphan Drugs in Europe: 130

Key Topics Covered:

1. What Are Orphan Drugs?

2. Europe Orphan Drug Designation Criteria

3. Europe Orphan Drug Reimbursement Policy

4. Europe Orphan Drug Market Overview

5. Europe Regulatory Framework for Orphan Drugs

6. Europe Orphan Drug Pipeline by Country, Company, Indication & Phase

7. Marketed Orphan Drug in Europe by Country, Company & Indication

8. Discontinued & Suspended Orphan Drug Clinical Pipeline

9. Competitive Landscape

  • AOP Orphan
  • Genethon
  • Genzyme Corporation
  • Glaxosmithkline
  • Merck
  • Novartis Pharmaceuticals
  • Orphan Europe
  • Pfizer
  • Prosensa
  • Shire
  • Teva Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/hhsmsd/europe_orphan